Research Collaboration Opportunity

Title: A safer, more effective clot-dissolving drug: Xai-K

PIs
Dr. Ed Pryzdial

Therapeutic Area
Thrombosis

Description
Xai-K rapidly dissolves clots as a primary therapeutic. It can also be used in combination with the prevailing thrombolytic drug, tPA, enabling reduced dosages to improve the safety profile of the latter for treatment of resistant thrombi. To avoid reocclusion, Xai-K was designed to dually function as an anticoagulant.

Research stage
The efficacy of Xai-K as both a primary and adjunctive therapeutic has been demonstrated in a pre-clinical murine model of occlusive thrombosis. Using Rayleigh light scattering, thromboelastography and numerous other in vitro techniques, its biochemistry has been analyzed.

Types of collaborations
Interested in a pharmaceutical partner that could fund and/or advise our studies on producing a recombinant version of Xai-K and to optimize the chemical composition of the modification that confers thrombolytic activity.

IP Status
Patents have been submitted in the US and Europe.

Contact
Dr. Ed Pryzdial
Scientist, Canadian Blood Services, Centre for Innovation
Associate Director, Centre for Blood Research
Clinical Professor, Department of Pathology and Laboratory Medicine
Associate Director, Exams, Graduate Studies Program
2350 Health Sciences Mall, Centre for Blood Research, Rm 4365
Life Sciences Centre, University of British Columbia,
Vancouver, Canada, V6T 1Z3
604-822-3823
http://cbr.ubc.ca/people/investigators/ed-pryzdial/